Welcome to our dedicated page for Ibio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading iBio’s disclosures can feel like deciphering lab notes—the 10-K alone details AI-guided antibody platforms, bioprocess scale-ups, and government contract clauses that span hundreds of pages. Need to spot clinical pipeline risks or funding triggers quickly? That’s exactly why investors start with Stock Titan.
Our AI breaks down every document the moment it hits EDGAR. Whether you’re tracking “iBio insider trading Form 4 transactions” or comparing cash-burn trends across the latest “iBio quarterly earnings report 10-Q filing”, you’ll see plain-English summaries, red-flag highlights, and side-by-side quarter comparisons. Form types are linked and clarified, so “understanding iBio SEC documents with AI” becomes routine, not a weekend project.
Questions about management sentiment? View “iBio Form 4 insider transactions real-time” alerts that reveal buying or selling within minutes of submission. Curious about capital needs or milestone payments? The platform tags each “iBio 8-K material events explained” entry so you can gauge impact instantly. When the comprehensive annual review lands, our engine delivers the “iBio annual report 10-K simplified”—pinpointing R&D spend, manufacturing capacity, and antibody program updates.
Dig deeper into governance with the fully linked “iBio proxy statement executive compensation”, or compare salary structures against “iBio earnings report filing analysis” to see if incentives align with pipeline milestones. And for a sharper lens on leadership moves, check the dedicated feed of “iBio executive stock transactions Form 4”.
From insider trades to trial readouts, every iBio filing is surfaced, summarized, and searchable—so you can act on data, not dig for it.
ADAR1-affiliated investors report beneficial ownership of 1,794,055 shares of iBio, Inc., representing 9.9% of the outstanding common stock. The holding comprises 54,819 shares held directly by ADAR1 Partners, LP and 1,739,236 shares issuable upon conversion of milestone warrants held by ADAR1 Partners, LP. The filing states that 716,904 additional shares underlying milestone warrants are excluded because their exchange or exercise is subject to a 9.99% beneficial ownership limitation.
The reporting entities are ADAR1 Capital Management, LLC (investment adviser), ADAR1 Capital Management GP, LLC (general partner) and Daniel Schneeberger (manager), each disclosing shared voting and dispositive power over the 1,794,055 shares. The ownership percentage is calculated on a stated base of 16,219,281 shares outstanding.
iBio, Inc. (Nasdaq: IBIO) has filed a Form 424(b)(3) prospectus dated June 23, 2025 to register the resale of up to 11,253,370 shares of common stock. The shares correspond to the same number of shares underlying New Warrants issued in a private placement completed on April 30, 2025 under an Inducement Agreement signed April 29, 2025.
- Warrant terms: exercise price $0.86, immediately exercisable, five-year term.
- Potential company proceeds: up to approximately $9.7 million in cash should all warrants be exercised.
- Use of prospectus: enables the Selling Stockholders (and their transferees) to sell shares at market, related, or negotiated prices; iBio will not receive sale proceeds but will cover registration expenses.
- Selling mechanics: shares may be sold via underwriters, brokers, or directly in public or private transactions as detailed in the “Plan of Distribution.”
- Listing information: IBIO last traded at $0.771 on June 20, 2025, below the warrant exercise price.
The filing satisfies iBio’s contractual obligation to register the shares, preserves potential capital inflow from future warrant exercises, and signals possible dilution if the warrants are exercised. Investors should consult the “Risk Factors” section on page 5 and the company’s SEC filings for further details.
On June 24, 2025, iBio, Inc. (Nasdaq: IBIO) filed a Form 8-K to inform the market that it has released an updated corporate presentation, dated June 2025. The slide deck, furnished as Exhibit 99.1, will be used in discussions with investors, analysts and other stakeholders. The filing is made under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). iBio states that the presentation includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995 and that the company assumes no obligation to update the material. No financial results, strategic transactions or other material developments are disclosed in this report.
The SEC has declared iBio's Form S-3 registration statement effective as of June 23, 2025, at 5:00 P.M. The registration statement was filed under file number 333-288000.
Form S-3 is a simplified security registration form used by companies that have already met certain reporting requirements. This effectiveness notice indicates that:
- iBio can now proceed with its planned securities offering
- The company has satisfied SEC registration requirements
- The registration statement has been reviewed and approved by the SEC
This filing suggests iBio is preparing to raise capital through the public markets, though specific details about the type and amount of securities to be offered would be found in the original S-3 filing and related prospectus.
FAQ
What is the current stock price of Ibio (IBIO)?
What is the market cap of Ibio (IBIO)?
